Document is current

Article History

Received: 28 August 2023

Accepted: 28 December 2023

First Online: 29 February 2024

Declarations

:

: The study was evaluated by the Ethical Committee of the University Duisburg-Essen (AZ:18-8389-BO). All participants were informed in detail about the aim and the planned investigations of the study and signed an informed consent before inclusion to the study.

: Not applicable.

: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. KB has served as a consultant, at advisory boards, or at data monitoring committees for BioArctic, Biogen, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).